M
Mitchell Dowsett
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 4
Citations - 4573
Mitchell Dowsett is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Breast cancer & Guideline. The author has an hindex of 4, co-authored 4 publications receiving 3173 citations. Previous affiliations of Mitchell Dowsett include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C. Wolff,M. Elizabeth H. Hammond,Kimberly H. Allison,Brittany E. Harvey,Pamela B. Mangu,John M. S. Bartlett,Michael Bilous,Ian O. Ellis,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Lisa M. McShane,Mitchell Dowsett +16 more
TL;DR: The HER2 testing algorithm for breast cancer is updated and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays.
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C. Wolff,M. Elizabeth H. Hammond,Kimberly H. Allison,Brittany E. Harvey,Pamela B. Mangu,John M. S. Bartlett,Michael Bilous,Ian O. Ellis,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Lisa M. McShane,Mitchell Dowsett +16 more
TL;DR: The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISh and IHC assays.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff,M. Elizabeth H. Hammond,Kimberly H. Allison,Brittany E. Harvey,Pamela B. Mangu,John M. S. Bartlett,Michael Bilous,Ian O. Ellis,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Lisa M. McShane,Mitchell Dowsett +16 more
TL;DR: In this article, the authors updated key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer.